Compared to Estimates, ResMed (RMD) Q2 Earnings: A Look at Key Metrics

For the quarter ended December 2024, ResMed (RMD) reported revenue of $1.28 billion, up 10.3% over the same period last year. EPS came in at $2.43, compared to $1.88 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.26 billion, representing a surprise of +1.57%. The company delivered an EPS surprise of +5.65%, with the consensus EPS estimate being $2.30.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how ResMed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: U.S., Canada, and Latin America- Devices: $414.50 million versus the four-analyst average estimate of $396.91 million. The reported number represents a year-over-year change of +11.6%. U.S., Canada, and Latin America- Masks and other: $334.50 million versus the four-analyst average estimate of $329.71 million. The reported number represents a year-over-year change of +12.3%. Combined Europe, Asia, and other markets- Total: $376.60 million versus the four-analyst average estimate of $373.11 million. The reported number represents a year-over-year change of +8.1%. Combined Europe, Asia, and other markets- Devices: $254.80 million versus $250.46 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +8.6% change. Combined Europe, Asia, and other markets- Masks and other: $121.80 million versus the four-analyst average estimate of $122.65 million. The reported number represents a year-over-year change of +6.9%. U.S., Canada, and Latin America- Total: $748.90 million versus the four-analyst average estimate of $726.61 million. The reported number represents a year-over-year change of +11.9%. Global revenue- Total Devices: $669.30 million versus the four-analyst average estimate of $647.36 million. The reported number represents a year-over-year change of +10.5%. Global revenue- Total Sleep and Respiratory Care: $1.13 billion versus $1.10 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.6% change. Global revenue- Total Masks and other: $456.30 million compared to the $452.36 million average estimate based on four analysts. The reported number represents a change of +10.8% year over year. View all Key Company Metrics for ResMed here>>>Shares of ResMed have returned +10.6% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ResMed Inc. (RMD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks